Prasad Sakshi, Jain Nityanand, Umar Tungki Pratama, Radenkov Igor, Ahmed Sirwan Khalid, Sakagianni Virginia, Kollia Sofia, Hingora Mohmed Junaid, Kumari Nikita, Akbari Amir Reza, Renemane Lubova, Bachu Anil
Faculty of Medicine, National Pirogov Memorial Medical University, Vinnytsia, Ukraine.
Faculty of Medicine, Riga Stradinš University, Riga, Latvia.
Front Psychiatry. 2023 Dec 22;14:1309986. doi: 10.3389/fpsyt.2023.1309986. eCollection 2023.
Posttraumatic stress disorder (PTSD) is a chronic disorder resulting from exposure to traumatic events. In recent years, sympathetic nerve blocks have gained interest as an emerging treatment modality for PTSD. They have been shown to reduce autonomic dysfunction associated with PTSD symptoms, particularly in refractory and treatment-resistant patients. However, there is limited evidence regarding the technique's effectiveness in PTSD patients. Therefore, this scoping review was designed to update and summarize the current literature on this topic to inform the design of future clinical trials and studies. Our review of 22 studies (mostly case reports and series) included 1,293 PTSD patients who received sympathetic nerve blocks, primarily military service members and veterans, with a median age of 42.2 years. 0.5% Ropivacaine was the preferred anesthetic, and the right sided stellate ganglion block was the most commonly used technique. Relapse of symptoms was reported commonly, resulting in additional nerve block sessions. Most reported side effects were mild and transient. Despite the encouraging results, we remain cautious in interpreting the benefit of the technique due to the lack of sufficient standardized clinical trial data, heterogeneity in reported results, and the potential for bias in reporting. Future studies should focus on evaluating and addressing the technique's effectiveness, safety, tolerability, and indications.
创伤后应激障碍(PTSD)是一种因暴露于创伤性事件而导致的慢性疾病。近年来,交感神经阻滞作为一种新兴的PTSD治疗方式受到了关注。研究表明,交感神经阻滞可减轻与PTSD症状相关的自主神经功能障碍,尤其是在难治性和治疗抵抗性患者中。然而,关于该技术在PTSD患者中的有效性的证据有限。因此,本范围综述旨在更新和总结关于这一主题的现有文献,为未来临床试验和研究的设计提供参考。我们对22项研究(主要是病例报告和系列研究)进行了综述,这些研究纳入了1293例接受交感神经阻滞的PTSD患者,主要是军人和退伍军人,中位年龄为42.2岁。0.5%罗哌卡因是首选的麻醉剂,右侧星状神经节阻滞是最常用的技术。症状复发较为常见,导致需要额外进行神经阻滞治疗。大多数报告的副作用轻微且短暂。尽管结果令人鼓舞,但由于缺乏足够的标准化临床试验数据、报告结果的异质性以及报告存在偏差的可能性,我们在解释该技术的益处时仍持谨慎态度。未来的研究应侧重于评估和解决该技术的有效性、安全性、耐受性和适应症。